119 related articles for article (PubMed ID: 1497392)
1. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
[TBL] [Abstract][Full Text] [Related]
2. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
[TBL] [Abstract][Full Text] [Related]
3. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
5. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
[TBL] [Abstract][Full Text] [Related]
6. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
[TBL] [Abstract][Full Text] [Related]
7. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
[TBL] [Abstract][Full Text] [Related]
8. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
9. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
[TBL] [Abstract][Full Text] [Related]
10. Different effects of heparin in males and females.
Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927
[TBL] [Abstract][Full Text] [Related]
11. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
12. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
13. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
Carter BL; Jones ME; Waickman LA
Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
[TBL] [Abstract][Full Text] [Related]
15. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
16. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
[TBL] [Abstract][Full Text] [Related]
17. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Baker BA; Adelman MD; Smith PA; Osborn JC
Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
[TBL] [Abstract][Full Text] [Related]
19. Heparin therapy in pediatric patients: a prospective cohort study.
Andrew M; Marzinotto V; Massicotte P; Blanchette V; Ginsberg J; Brill-Edwards P; Burrows P; Benson L; Williams W; David M
Pediatr Res; 1994 Jan; 35(1):78-83. PubMed ID: 8134203
[TBL] [Abstract][Full Text] [Related]
20. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
Hull R; Hirsh J; Jay R; Carter C; England C; Gent M; Turpie AG; McLoughlin D; Dodd P; Thomas M; Raskob G; Ockelford P
N Engl J Med; 1982 Dec; 307(27):1676-81. PubMed ID: 6755255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
